Orazio Caffo1, Gaetano Facchini2, Elisa Biasco3, Francesco Ferraù4, Franco Morelli5, Maddalena Donini6, Consuelo Buttigliero7, Nicola Calvani8, Annalisa Guida9, Vincenzo Emanuele Chiuri10, Umberto Basso11, Claudia Mucciarini12, Vincenza Conteduca13, Sabrina Rossetti2, Antonello Veccia14, Francesca Maines14, Stefania Kinspergher14, Ugo De Giorgi13. 1. Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38122 Trento, Italy. 2. Departmental Unit of Clinical & Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G Pascale, Via Mariano Semmola 52, 80131 Naples, Italy. 3. Oncology Unit 2, University Hospital, Via Paradisa 2, 56124 Pisa, Italy. 4. Medical Oncology Department, San Vincenzo Hospital, Via Sirina, 98039 Taormina, Italy. 5. Medical Oncology Department, Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013 San Giovanni Rotondo, Italy. 6. Medical Oncology Department, General Hospital, Viale Concordia, 26100 Cremona, Italy. 7. Medical Oncology Department, University of Torino, San Luigi Hospital, Regione Gonzole 10, 10043 Orbassano, Italy. 8. Medical Oncology Division & Breast Unit, Antonio Perrino Hospital, 72100 Brindisi, Italy. 9. Medical Oncology Division, Azienda Ospedaliero Universitaria, Policlinico di Modena, 41100 Modena, Italy. 10. Medical Oncology Unit, Vito Fazzi Hospital, 73100 Lecce, Italy. 11. Medical Oncology Unit 1, Istituto Oncologico Veneto IOV, IRCCS, 35128 Padua, Italy. 12. Medical Oncology Department, General Hospital, 41012 Carpi, Italy. 13. Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. 14. Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38122 Trento, Italy.
Abstract
AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients. PATIENTS & METHODS: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once-daily oral mCTX treatment at a fixed dose of 50 mg. RESULTS: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months. CONCLUSIONS: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.
AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients. PATIENTS & METHODS: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once-daily oral mCTX treatment at a fixed dose of 50 mg. RESULTS: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months. CONCLUSIONS: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.
Entities:
Keywords:
castration-resistant prostate cancer; cyclophosphamide; fourth line; third line